Replies to post #219784 on Biotech Values

[dewophile]

melanoma is a high mutational burden cancer in general so perhaps many of the pd-L1 negatives respond in the same way that lung patients who are pd-L1 low and TMB high responded to opdivo/ipi
FWIW in the opdivo adjuvant melanoma study the HR in PD-L1 high patients was more pronounced relative to total population than in the keytruda study.